Adderall
A 3:1 mixture of dextro-amphetamine to levo-amphetamine salts and is used to treat attention deficit hyperactivity disorder. The brand Adderall® is marketed by Shire Pharmaceuticals.
History
In the United States, the mixture was approved with a New Drug Application (NDA) by the FDA in 1960.[1] The extended release version was approved in 2001.[2] A generic version (not extended release) was approved with a Abbreviated New Drug Application (ANDA) in 2002.[3]
Pharmacokinetics
The time to reach maximum plasma concentration is:[4]
- Adderall XR® is about 7 hours
- Addreall 3 hours
Adderall XR 20 mg one daily has similar pharmacokinetics to Adderall(immediate-release) 10 mg twice dialy administered 4 hours apart. [4]
The mean elimination half-life in adults for d-amphetamine is 10 hours and for the l-amphetamine is 13 hours[4]
External links
The most up-to-date information about Adderall and other drugs can be found at the following sites.
- Adderall - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Adderall - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Adderall - Detailed information from DrugBank.
References
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ 4.0 4.1 4.2 Adderall XR (Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate and Amphetamine Aspartate) capsule, extended release [Shire US Inc.]